title: Chitosan-coated superparamagnetic iron oxide nanoparticles for doxorubicin delivery: synthesis and anticancer effect against human ovarian cancer cells.
abstract: Doxorubicin-loaded chitosan-coated superparamagnetic iron oxide nanoparticles (Fe3 O4 ; SPIO-NPs) were prepared by coprecipitation and emulsification cross-linking method and uniform NPs with an average particle size of 82 nm, with high encapsulation efficiencies, were obtained. The drug-loading efficiency of doxorubicin (3.2 mg/mg NPs) showed better results for the chitosan-loaded SPIO-NPs as compared to the bare ones (0.5 mg/mg; p < 0.05). The incubation of A2780 and OVCAR-3 human ovarian cancer cells with doxorubicin-loaded and doxorubicin-loaded chitosan-coated SPIO-NPs, for 24, 48, 72, 96, and 120 h, showed significant IC50 (2.0 ± 0.6 and 7.1 ± 2.7 mm doxorubicin) and IC90 (4.0 ± 9.2 and 10 ± 0.5 mm doxorubicin), respectively, after 96 h of incubation. While, 95% and 98% growth inhibition was seen in A2780 and OVCAR-3 cells after the 96-h exposure to the doxorubicin-chitosan-SPIO-NPs (p < 0.05). A 5-day (120 h) incubation with doxorubicin-chitosan-SPIO-NPs showed that A2780 and OVCAR-3 cells were able to uptake 120 and 110 pg iron/cell, respectively, when treated with doxorubicin-chitosan-SPIO-NPs for 72 h (p < 0.05).
authors.affiliation: Department of Biochemistry, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
authors.forename: Amaneh
authors.initials: A
authors.lastname: Javid
authors.forename: Shahin
authors.initials: S
authors.lastname: Ahmadian
authors.forename: Ali A
authors.initials: AA
authors.lastname: Saboury
authors.forename: Seyed M
authors.initials: SM
authors.lastname: Kalantar
authors.forename: Saeed
authors.initials: S
authors.lastname: Rezaei-Zarchi
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000737:chemistry* / Q000633:toxicity; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D048271:Chitosan / Q000737:chemistry*; D004317:Doxorubicin / Q000737:chemistry* / Q000633:toxicity; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D005290:Ferric Compounds / Q000737:chemistry*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D058185:Magnetite Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D016328:NF-kappa B / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology; D010316:Particle Size; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D000077022:Survivin; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; C107489:BIRC5 protein, human; D004337:Drug Carriers; D005290:Ferric Compounds; D051034:Inhibitor of Apoptosis Proteins; D058185:Magnetite Nanoparticles; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D000077022:Survivin; D051028:bcl-2-Associated X Protein; C000499:ferric oxide; D004317:Doxorubicin; D048271:Chitosan
keywords: chitosan; doxorubicin; drug loading; encapsulation; human ovarian cancer; iron oxide